Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Regadenoson - Astellas Pharma/Rapidscan Pharma Solutions/Gilead Sciences

Next Previous
Drug Profile

Regadenoson - Astellas Pharma/Rapidscan Pharma Solutions/Gilead Sciences

Alternative Names: CVT 3146; Lexiscan; Rapiscan

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CV Therapeutics
  • Developer Astellas Pharma; Gilead Sciences; National Jewish Health; Rapidscan Pharma Solutions
  • Class Imaging agents; Purines; Pyrazoles; Small molecules; Vasodilators
  • Mechanism of Action Adenosine A2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Coronary disorders
  • No development reported Pulmonary hypertension

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 14 Jun 2018 Medical University of South Carolina and Astellas Pharma completes a phase II trial in Coronary disorders (Diagnosis) in USA (NCT03103061)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pulmonary-hypertension in USA (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top